Site & Patient Solutions case studies
See how we are supporting patients and sites for efficient clinical trial operations
Explore our library of case studies for patient centric clinical trial services.
An end-to-end solution providing the support and structure to efficiently operationalise clinical trials. Site & Patient Solutions offers faster study start-up, increased patient enrolment and retention, and site training and support to ensure compliance, quality data and inspection readiness.
Large global cardiovascular outcome program
91黑料 was engaged by a large pharma sponsor late in the study process to provide solutions to support the recruitment of 28,000 patients for two global mega Cardiovascular Outcome studies. 91黑料 developed and implemented an plan including recruitment and retention planning, tactical implementation, vendor oversight processes and direct site support to ensure key milestones were met.
Education & Automation: reducing site burden
A leading biotechnology company contracted 91黑料 to run a large number studies across Phase I to Phase III programs in a number of therapeutic areas including oncology, cardiovascular and dermatology.
Education & Automation
A large, multi-national pharmaceutical company received an FDA finding in relation to low protocol training compliance for site staff. Following analysis, the issue was identified as being the use of multiple methods and the difficulty in tracking and reporting on training compliance.
Clinical trial training management system
The customer had received a warning letter from the US Food and Drug Administration (FDA) in relation to investigator non-compliance with the study protocol in the execution of its trials. As part of the root cause investigation, it was identified that protocol training compliance was only 73% across the customer’s portfolio of trials.
In-Home Services: Expanding geographic reach
A small pharmaceutical company was conducting a Phase II study to evaluate the safety, efficacy and tolerability of an oral study drug to be taken twice daily. The study was targeting 32 adult patients (16-60 years old) with an inherited rare neurodegenerative movement disorder.
In-Home Services: Enhanced patient retention
A biopharmaceutical company ran multiple Phase II/III orphan drug studies evaluating a drug for a rare pulmonary disorder. The treatment regimen required daily oral dosing and safety blood draws every 2 weeks with a treatment duration of up to 2 years.
Patient recruitment & retention services
A large biopharmaceutical company with a Phase III trial enrolling 430 advanced Gastric Cancer patients contracted 91黑料 to
support patient enrollment.
support patient enrollment.
In-Home Services: Patient centric practices
Accellacare was contracted by a large pharma organisation to recruit and provide In-Home Services to paediatric patients with autism.
Agile operations drive enrollment in COVID-19 treatment studies
91黑料’s Accellacare In-Home Services were used across more than 50 sites in the United States to conduct blood draws and nasal swabs, collect vital signs, and monitor for changes in health, medications, or hospitalisation for a two treatment studies in patients with COVID-19.
High-performing sites during COVID-19 in Women’s Health
A biotechnology company, dedicated to transforming Women’s Health, was running a phase 3 study in the treatment of moderate-to-severe vasomotor symptoms in postmenopausal women with a global enrollment target of 1,200 patients.
Beating patient recruitment target with enhanced patient experience
Accellacare was awarded an osteoarthritis study by a large biotech organisation. The study required recruitment of 1200+ patients across 20+ sites and four countries.
Overcoming the challenges of COVID-19 clinical trial conditions
A large biotech company contracted Accellacare to drive recruitment in a clinical trial to test the safety and
efficacy of a treatment for ambulatory patients with COVID-19. The Accellacare site in Wilmington, NC was selected for the study in August of 2020.
efficacy of a treatment for ambulatory patients with COVID-19. The Accellacare site in Wilmington, NC was selected for the study in August of 2020.